Amneal Pharmaceuticals Quarterly Balance Sheet
NASDAQ: AMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amneal Pharmaceuticals financial position
As of Jun 30, 2026, Amneal Pharmaceuticals reported total assets of $3.78 billion, up 10.3% from a year earlier against total liabilities of $3.74 billion. Shareholders' equity stood at $33.0 million, or 0.9% of assets. The company held $127.6 million in cash and equivalents against $2.57 billion of debt, a net debt position of $2.44 billion.
The current ratio (current assets divided by current liabilities) was 2.20, meaning short-term assets cover obligations due within a year. Debt-to-equity was 77.83.
Summary generated from market data by MetaCap's automated system. Methodology
Amneal Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 127.64M | 197.66M | 282.03M | 201.25M | 71.54M | 59.19M | 110.55M | 74.01M | 43.77M | 46.52M | 91.54M | 86.93M |
| Inventory | 677.95M | 641.62M | 606.30M | 614.50M | 608.97M | 601.43M | 612.45M | 596.36M | 575.62M | 570.65M | 581.38M | 576.47M |
| Total Current Assets | 1.95B | 1.80B | 1.91B | 1.84B | 1.58B | 1.51B | 1.59B | 1.51B | 1.49B | 1.38B | 1.38B | 1.46B |
| Property, Plant & Equipment | 456.88M | 444.61M | 442.95M | 434.99M | 440.33M | 427.23M | 424.91M | 431.02M | 425.38M | 439.81M | 447.57M | 451.85M |
| Goodwill | 593.50M | 593.80M | 595.47M | 595.95M | 597.41M | 597.50M | 597.44M | 598.32M | 598.53M | 598.55M | 598.63M | 598.63M |
| Intangible Assets | 587.83M | 534.87M | 563.50M | 587.94M | 649.55M | 689.14M | 732.38M | 780.19M | 819.94M | 859.27M | 890.42M | 982.53M |
| Total Assets | 3.78B | 3.54B | 3.68B | 3.60B | 3.42B | 3.37B | 3.50B | 3.46B | 3.51B | 3.46B | 3.47B | 3.69B |
| Accounts Payable | — | — | — | 266.36M | 205.81M | 192.53M | 258.69M | 235.00M | 199.58M | 175.32M | 143.57M | 177.40M |
| Short-Term Debt | 5.96M | 6.20M | 6.76M | 7.20M | 31.18M | 31.79M | 224.21M | 224.69M | 225.16M | 33.66M | 34.13M | 30.53M |
| Total Current Liabilities | 883.19M | 728.05M | 881.63M | 862.11M | 1.11B | 1.08B | 1.13B | 1.10B | 1.11B | 834.39M | 846.60M | 760.60M |
| Long-Term Debt | 2.56B | 2.57B | 2.57B | 2.57B | 2.15B | 2.15B | 2.16B | 2.17B | 2.18B | 2.38B | 2.39B | 2.54B |
| Total Liabilities | 3.74B | 3.59B | 3.75B | 3.71B | 3.54B | 3.50B | 3.61B | 3.55B | 3.57B | 3.52B | 3.45B | 3.53B |
| Shareholders' Equity | 33.02M | -45.41M | -70.79M | -109.46M | -112.12M | -131.67M | -109.27M | -93.43M | -57.47M | -63.72M | 19.78M | 330.86M |
| Retained Earnings | -415.09M | -472.75M | -535.00M | -570.08M | -572.45M | -594.87M | -607.06M | -575.98M | -575.83M | -581.82M | -490.18M | -391.53M |
| Total Debt | 2.57B | 2.57B | 2.57B | 2.57B | 2.18B | 2.19B | 2.39B | 2.39B | 2.40B | 2.41B | 2.42B | 2.57B |
| Net Cash (Debt) | -2.44B | -2.37B | -2.29B | -2.37B | -2.11B | -2.13B | -2.28B | -2.32B | -2.36B | -2.36B | -2.33B | -2.49B |
This table shows 12 quarterly periods of Amneal Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow AMRX's reporting calendar. What is a balance sheet?